Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
2.

MALDI-MS Protein Profiling of Chemoresistance in Extracellular Vesicles of Cancer Cells.

Stübiger G, Nairn MD, Abban TK, Openshaw ME, Mancera L, Herzig B, Wuczkowski M, Senfter D, Mader RM.

Anal Chem. 2018 Nov 20;90(22):13178-13182. doi: 10.1021/acs.analchem.8b03756. Epub 2018 Nov 1.

PMID:
30383359
3.

Acute molecular effects of pressure-controlled intermittent coronary sinus occlusion in patients with advanced heart failure.

Mohl W, Spitzer E, Mader RM, Wagh V, Nguemo F, Milasinovic D, Jusić A, Khazen C, Szodorai E, Birkenberg B, Lubec G, Hescheler J, Serruys PW.

ESC Heart Fail. 2018 Dec;5(6):1176-1183. doi: 10.1002/ehf2.12354. Epub 2018 Sep 19.

4.

Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.

Schoergenhofer C, Schwameis M, Firbas C, Bartko J, Derhaschnig U, Mader RM, Plaßmann RS, Jilma-Stohlawetz P, Desai K, Misra P, Jäger U, Jilma B.

Sci Rep. 2018 Jan 9;8(1):124. doi: 10.1038/s41598-017-17934-6.

5.

Intravasation of SW620 colon cancer cell spheroids through the blood endothelial barrier is inhibited by clinical drugs and flavonoids in vitro.

Holzner S, Brenner S, Atanasov AG, Senfter D, Stadler S, Nguyen CH, Fristiohady A, Milovanovic D, Huttary N, Krieger S, Bago-Horvath Z, de Wever O, Tentes I, Özmen A, Jäger W, Dolznig H, Dirsch VM, Mader RM, Krenn L, Krupitza G.

Food Chem Toxicol. 2018 Jan;111:114-124. doi: 10.1016/j.fct.2017.11.015. Epub 2017 Nov 10.

PMID:
29129665
6.

OncomiR-17-5p: alarm signal in cancer?

Bobbili MR, Mader RM, Grillari J, Dellago H.

Oncotarget. 2017 Jul 18;8(41):71206-71222. doi: 10.18632/oncotarget.19331. eCollection 2017 Sep 19. Review.

7.

Thiosemicarbazone derivatives, thiazolyl hydrazones, effectively inhibit leukemic tumor cell growth: Down-regulation of ribonucleotide reductase activity and synergism with arabinofuranosylcytosine.

Graser-Loescher G, Schoenhuber A, Ciglenec C, Eberl S, Krupitza G, Mader RM, Jadav SS, Jayaprakash V, Fritzer-Szekeres M, Szekeres T, Saiko P.

Food Chem Toxicol. 2017 Oct;108(Pt A):53-62. doi: 10.1016/j.fct.2017.07.029. Epub 2017 Jul 14.

PMID:
28716444
8.

Non-coding RNAs, the Trojan horse in two-way communication between tumor and stroma in colorectal and hepatocellular carcinoma.

Cătană CS, Pichler M, Giannelli G, Mader RM, Berindan-Neagoe I.

Oncotarget. 2017 Apr 25;8(17):29519-29534. doi: 10.18632/oncotarget.15706. Review.

9.

Extravasation emergencies: state-of-the-art management and progress in clinical research.

Pluschnig U, Haslik W, Bartsch R, Mader RM.

Memo. 2016;9(4):226-230. doi: 10.1007/s12254-016-0304-2. Epub 2016 Dec 5. Review.

10.

Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca2+ signalling.

Stadler S, Nguyen CH, Schachner H, Milovanovic D, Holzner S, Brenner S, Eichsteininger J, Stadler M, Senfter D, Krenn L, Schmidt WM, Huttary N, Krieger S, Koperek O, Bago-Horvath Z, Brendel KA, Marian B, de Wever O, Mader RM, Giessrigl B, Jäger W, Dolznig H, Krupitza G.

Cell Mol Life Sci. 2017 May;74(10):1907-1921. doi: 10.1007/s00018-016-2441-5. Epub 2016 Dec 24.

11.

The microRNA-200 family: still much to discover.

Senfter D, Madlener S, Krupitza G, Mader RM.

Biomol Concepts. 2016 Dec 1;7(5-6):311-319. doi: 10.1515/bmc-2016-0020. Review.

PMID:
27837593
12.

Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro.

Holzner S, Senfter D, Stadler S, Staribacher A, Nguyen CH, Gaggl A, Geleff S, Huttary N, Krieger S, Jäger W, Dolznig H, Mader RM, Krupitza G.

Oncol Rep. 2016 Nov;36(5):3065-3071. doi: 10.3892/or.2016.5114. Epub 2016 Sep 20.

PMID:
27666412
13.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

14.

NFκB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.

Körber MI, Staribacher A, Ratzenböck I, Steger G, Mader RM.

Anticancer Res. 2016 Apr;36(4):1631-9.

PMID:
27069140
15.

The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation.

Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Phytomedicine. 2015 Aug 15;22(9):862-74. doi: 10.1016/j.phymed.2015.06.003. Epub 2015 Jun 26.

PMID:
26220634
16.

miR-135b- and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.

Fetahu IS, Tennakoon S, Lines KE, Gröschel C, Aggarwal A, Mesteri I, Baumgartner-Parzer S, Mader RM, Thakker RV, Kállay E.

Int J Cancer. 2016 Jan 1;138(1):137-45. doi: 10.1002/ijc.29681. Epub 2015 Oct 1.

17.

Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro.

Senfter D, Holzner S, Kalipciyan M, Staribacher A, Walzl A, Huttary N, Krieger S, Brenner S, Jäger W, Krupitza G, Dolznig H, Mader RM.

Hum Mol Genet. 2015 Jul 1;24(13):3689-98. doi: 10.1093/hmg/ddv113. Epub 2015 Apr 1.

PMID:
25832648
18.

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.

19.

Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS).

Egger AE, Kornauth C, Haslik W, Hann S, Theiner S, Bayer G, Hartinger CG, Keppler BK, Pluschnig U, Mader RM.

Metallomics. 2015 Mar;7(3):508-15. doi: 10.1039/c4mt00308j.

PMID:
25659827
20.

Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.

Haslik W, Hacker S, Felberbauer FX, Thallinger C, Bartsch R, Kornauth C, Deutschmann C, Mader RM.

Eur J Surg Oncol. 2015 Mar;41(3):378-85. doi: 10.1016/j.ejso.2014.11.042. Epub 2014 Dec 4.

PMID:
25515823
21.

Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.

Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, Lajter I, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G.

Cancer Lett. 2015 Jan 28;356(2 Pt B):994-1006. doi: 10.1016/j.canlet.2014.11.019. Epub 2014 Nov 15.

PMID:
25444930
22.

Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol.

Pluschnig U, Haslik W, Bayer G, Soleiman A, Bartsch R, Lamm W, Steger GG, Zielinski CC, Mader RM.

Support Care Cancer. 2015 Jun;23(6):1741-8. doi: 10.1007/s00520-014-2535-2. Epub 2014 Nov 30.

PMID:
25433440
23.

Indocyanine green video angiography predicts outcome of extravasation injuries.

Haslik W, Pluschnig U, Steger GG, Zielinski CC, Schrögendorfer KF, Nedomansky J, Bartsch R, Mader RM.

PLoS One. 2014 Aug 21;9(8):e103649. doi: 10.1371/journal.pone.0103649. eCollection 2014.

24.

Translating the molecular analysis of cancer biology into therapeutic concepts.

Mader RM, Brodowicz T, Zielinski CC.

Cancer Biomark. 2014;14(2-3):87-91. doi: 10.3233/CBM-130382.

PMID:
24878809
25.

Drug resistance mediated changes in lymphendothelial tumor cell intravasation.

Senfter D, Huttary N, Krupitza G, Dolznig H, Mader RM.

Int J Clin Pharmacol Ther. 2014 Jan;52(1):82-4. doi: 10.5414/CPXCES13EA04. No abstract available.

PMID:
24321211
26.

NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down-regulate microRNA related to epithelial-mesenchymal transition.

Mader RM, Foerster S, Sarin N, Michaelis M, Cinatl J Jr, Kloft C, Fröhlich H, Engel F, Kalayda GV, Jäger W, Frötschl R, Jaehde U, Ritter CA.

Int J Clin Pharmacol Ther. 2014 Jan;52(1):92-4. doi: 10.5414/CPXCES13EA08. No abstract available.

PMID:
24219969
27.

Exosomal microRNA transfer varies with specific microRNAs functional in colorectal cancer and cellular differentiation.

Moshammer MI, Kalipciyan M, Bartsch R, Steger GG, Sedivy R, Mader RM.

Int J Clin Pharmacol Ther. 2014 Jan;52(1):87-8. doi: 10.5414/CPXCES13EA06. No abstract available.

PMID:
24219968
28.

A systems pharmacology approach to improve drug therapy in NSCLC: establishing a CESAR network.

Kalayda GV, Michaelis M, Cinatl J Jr, Mader RM, Fröhlich H, Sarin N, Melin J, Engel F, Jäger W, Frötschl R, Jaehde U, Kloft C, Ritter CA.

Int J Clin Pharmacol Ther. 2014 Jan;52(1):89-91. doi: 10.5414/CPXCES13EA07. No abstract available.

PMID:
24216144
29.

microRNA expression profiles distinguish colorectal cancer patients in two regions of Austria.

Moshammer MI, Kalipciyan M, Offner F, Sterlacci W, Steger GG, Mader RM, Sedivy R.

Int J Clin Pharmacol Ther. 2014 Jan;52(1):85-6. doi: 10.5414/CPXCES13EA05. No abstract available.

PMID:
24216143
30.

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.

Giessrigl B, Schmidt WM, Kalipciyan M, Jeitler M, Bilban M, Gollinger M, Krieger S, Jäger W, Mader RM, Krupitza G.

Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.

31.

NF-κB addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model.

Körber MI, Klingenbrunner S, Bartsch R, Steger GG, Mader RM.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):35-7. No abstract available.

32.

A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.

Hobl EL, Mader RM, Jilma B, Duhm B, Mustak M, Bröll H, Högger P, Erlacher L.

Clin Ther. 2012 May;34(5):1195-203. doi: 10.1016/j.clinthera.2012.03.059. Epub 2012 Apr 18.

PMID:
22516039
33.

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG.

Eur J Cancer. 2012 Sep;48(13):1932-8. doi: 10.1016/j.ejca.2012.03.002. Epub 2012 Mar 27.

PMID:
22459763
34.

Brain metastases free survival differs between breast cancer subtypes.

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10.

35.

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader RM.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.

PMID:
22152098
36.

The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.

Hobl EL, Mader RM, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Kalipciyan M, Jilma B.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):963-9. Epub 2011 Dec 22.

PMID:
22133036
37.

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG.

Br J Cancer. 2012 Jan 3;106(1):25-31. doi: 10.1038/bjc.2011.531. Epub 2011 Nov 29.

38.

KRAS mutations in historical tumour specimens of the Viennese Museum of pathological anatomy.

Sedivy R, Kalipciyan M, Patzak B, Mader RM.

Histopathology. 2011 Apr;58(5):792-6. doi: 10.1111/j.1365-2559.2011.03832.x. Epub 2011 Apr 4. No abstract available.

PMID:
21457164
39.

Cross-resistance of 5-fluorouracil-resistant colon carcinoma in vitro.

Ratzenboeck IE, Bartl B, Forstner B, Kalipciyan M, Steger GG, Mader RM.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):81-2. No abstract available.

PMID:
21176738
40.

Suicide activation in a 5-fluorouracil resistant colon cancer model in vitro.

Mader RM, Kalipciyan M, Ohana P, Hochberg A, Steger GG.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):69-70. No abstract available.

PMID:
21176733
41.

Relevance of microRNA modulation in chemoresistant colon cancer in vitro.

Mader RM, Wieser M, Berger W, Kalipciyan M, Hackl M, Steger GG, Grillari J.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):67-8. No abstract available.

PMID:
21176732
42.

Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620.

Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, Mader RM.

Exp Cell Res. 2010 Nov 15;316(19):3172-81. doi: 10.1016/j.yexcr.2010.09.003. Epub 2010 Sep 21.

PMID:
20849845
43.

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG.

BMC Cancer. 2009 Oct 17;9:367. doi: 10.1186/1471-2407-9-367.

44.

Molecular mechanisms of drug resistance.

Mader RM, Schmidt WM, Steger GG, Krupitza G.

Int J Clin Pharmacol Ther. 2009 Jan;47(1):49-50. No abstract available.

PMID:
19203537
45.

Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate--preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy.

Grim-Stieger M, Keilani M, Mader RM, Marosi C, Schmidinger M, Zielinski CC, Fialka-Moser V, Crevenna R.

Eur J Cancer Care (Engl). 2008 Sep;17(5):454-62. doi: 10.1111/j.1365-2354.2007.00874.x. Epub 2008 Jul 17.

PMID:
18637115
46.

Longitudinal biomonitoring of nurses handling antineoplastic drugs.

Mader RM, Kokalj A, Kratochvil E, Pilger A, Rüdiger HW.

J Clin Nurs. 2009 Jan;18(2):263-9. doi: 10.1111/j.1365-2702.2007.02189.x.

PMID:
18624785
47.

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.

Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG.

Cancer Chemother Pharmacol. 2008 Oct;62(5):903-10. doi: 10.1007/s00280-008-0682-1. Epub 2008 Feb 7.

PMID:
18256835
48.

Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater.

Lenz K, Mahnik SN, Weissenbacher N, Mader RM, Krenn P, Hann S, Koellensperger G, Uhl M, Knasmüller S, Ferk F, Bursch W, Fuerhacker M.

Water Sci Technol. 2007;56(12):141-9.

PMID:
18075190
49.

Angiogenic effect of naive and 5-fluorouracil resistant colon carcinoma on endothelial cells in vitro.

Schönau KK, Steger GG, Mader RM.

Cancer Lett. 2007 Nov 8;257(1):73-8. Epub 2007 Aug 7.

PMID:
17686575
50.

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG.

J Clin Oncol. 2007 Sep 1;25(25):3853-8. Epub 2007 Aug 6.

PMID:
17679724

Supplemental Content

Loading ...
Support Center